Medan Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.10 M
as on 22-12-2024
- Paid Up Capital ₹ 3.10 M
as on 22-12-2024
- Company Age 11 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.20 M
as on 22-12-2024
- Revenue 12.01%
(FY 2023)
- Profit 124.74%
(FY 2023)
- Ebitda 252.03%
(FY 2023)
- Net Worth 1.93%
(FY 2023)
- Total Assets 6.36%
(FY 2023)
About Medan Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.10 M and a paid-up capital of Rs 3.10 M.
The company currently has active open charges totaling ₹7.20 M.
Deepa Veetil, Kalla Nidhin, Arjun Thekadavan, and One other member serve as directors at the Company.
- CIN/LLPIN
U52100KL2013PTC035434
- Company No.
035434
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Nov 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Kannur, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Medan Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepa Veetil  | Managing Director | 18-Nov-2013 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kalla Nidhin | Director | 26-Oct-2022 | Current |
| Arjun Thekadavan | Director | 26-Oct-2022 | Current |
| Vipin Veedu | Director | 26-Oct-2022 | Current |
Financial Performance of Medan Pharmaceuticals.
Medan Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.01% increase. The company also saw a substantial improvement in profitability, with a 124.74% increase in profit. The company's net worth moved up by a moderate rise of 1.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medan Pharmaceuticals?
Unlock access to Medan Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Octette Pharmaceuticals Private LimitedActive 3 years 4 monthsDeepa Veetil and Kalla Nidhin are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 18 Mar 2022 | ₹4.50 M | Open |
Punjab National Bank Creation Date: 16 Feb 2016 | ₹2.70 M | Open |
How Many Employees Work at Medan Pharmaceuticals?
Medan Pharmaceuticals has a workforce of 15 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medan Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medan Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
